



Fabrazyme (agalsidase)

Effective Date: January 1, 2021

Number: MG.MM.PH.311

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to, EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP), ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Fabrazyme is human α -galactosidase A (α -Gal), with the same amino acid sequence as the native enzyme. It is produced in Chinese hamster ovary cells via recombinant DNA technology. Fabrazyme catalyzes the breakdown of globotriaosylceramide (GL-3) and other α -galactyl-terminated neutral glycosphingolipids to ceramide and galactose. Fabrazyme is indicated for use in patients with Fabry disease. It reduces the deposition of GL-3 in the capillary endothelium of the kidney and certain other cell types.

Dosing

Each dose must not exceed 1 mg/kg administered intravenously no more frequently than once every 2 weeks.

Length of Coverage

- Approvals will be granted for 12 months

Guideline

Fabry Disease

- The diagnosis is established by one of the following:

- Patient has a laboratory test demonstrating deficient α -galactosidase A activity in leukocytes or fibroblasts; **OR**
- Patient has a molecular genetic test demonstrating mutations in the galactosidase alpha gene; **AND**
- Fabrazyme is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

Limitations/Exclusions

- Coverage is not recommended for circumstances not listed in the Guideline. Criteria will be updated as new published data are available.

Applicable Procedure Codes

J0180	Injection, agalsidase beta, 1 mg; 1 billable unit = 1 mg
-------	--

Applicable Procedure Codes

54868-0041-xx	Fabrazyme 5 mg single-use vial for injection
54868-0040-xx	Fabrazyme 35 mg single-use vial for injection

Applicable Diagnosis Codes

E75.21	Fabry (-Anderson) disease
--------	---------------------------

Revisions

1/1/2021	Criteria apply to Commercial, Medicare, and Medicaid members.
----------	---

REFERENCES

1. Fabrazyme® injection [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2018.
2. Schiffmann R. Fabry Disease. *Handb Clin Neurol*. 2015;132:231-248.
3. Arends M, Wanner C, Hughes D, et al. Characterization of Classical and Nonclassical Fabry Disease: A Multinational Study. *J Am Soc Nephrol*. 2017;28:1631-1641.
4. Laney DA, Bennett RL, Clarke V, et al. Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors. *J Genet Counsel*. 2013;22:555-564.